Jyong Biotech Ltd. Ordinary Shares's EBIT is $-2.6M, below the Healthcare sector average of $1.1T.
Get informed when a big investor buys or sells
+ FollowAs of Dec 31, 2025
Trailing 12 months ending Dec 31, 2025
The latest EBIT for MENS is $-2.6M as of December 2025. That compares with $-2.3K in the prior-year period — down 111896.9% year over year. That is below the Healthcare sector average of $1.1T. Investors often review this figure alongside Jyong Biotech Ltd. Ordinary Shares's historical trend and sector peers before judging valuation or financial health.
Over the past year, MENS's EBIT moved from $-2.3K to $-2.6M — a 111896.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Jyong Biotech Ltd. Ordinary Shares's operating scale or balance-sheet position.
Against Healthcare companies, MENS currently prints $-2.6M for EBIT, while the sector average sits near $1.1T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Jyong Biotech Ltd. Ordinary Shares's growth, margins, and balance sheet.
A EBIT figure of $-2.6M for MENS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.1T. Explore the charts below for those layers of context.
After noting MENS's EBIT ($-2.6M), review year-over-year change from $-2.3K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.